Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort

Claudia Elera-Fitzcarrald; Cristina Reatégui-Sokolova; Rocío V. Gamboa-Cárdenas; Mariela Medina; Francisco Zevallos; Victor R. Pimentel-Quiroz; Jorge M. Cucho-Venegas; José L. Alfaro-Lozano; Zoila Rodriguez-Bellido; Cesar A. Pastor-Asurza; Risto Perich-Campos; Graciela S. Alarcón; Manuel F. Ugarte-Gil

doi:10.1177/09612033211061481

Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort

Claudia Elera-Fitzcarrald, Cristina Reatégui-Sokolova, Rocío V. Gamboa-Cárdenas, Mariela Medina, Francisco Zevallos, Victor R. Pimentel-Quiroz, Jorge M. Cucho-Venegas, José L. Alfaro-Lozano, Zoila Rodriguez-Bellido, Cesar A. Pastor-Asurza, Risto Perich-Campos, Graciela S. Alarcón, Manuel F. Ugarte-Gil

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Objectives: This study aims to determine whether the MetS predicts damage accrual in SLE patients. Methods: This longitudinal study was conducted in a cohort of consecutive SLE patients seen since 2012 at one single Peruvian institution. Patients had a baseline visit and then follow-up visits every 6 months. Patients with ≥ 2 visits were included. Evaluations included interview, medical records review, physical examination, and laboratory tests. Damage accrual was ascertained with the SLICC/ACR damage index (SDI) and disease activity with the SLEDAI-2K. Univariable and multivariable Cox-regression survival models were carried out to determine the risk of developing new damage. The multivariable model was adjusted for age at diagnosis; disease duration; socioeconomic status; SLEDAI; baseline SDI; the Charlson Comorbidity Index; daily dose; and time of exposure of prednisone (PDN), antimalarials, and immunosuppressive drugs. Results: Two hundred and forty-nine patients were evaluated; 232 of them were women (93.2%). Their mean (SD) age at diagnosis was 35.8 (13.1) years; nearly all patients were Mestizo. Disease duration was 7.4 (6.6) years. The SLEDAI-2K was 5.2 (4.3) and the SDI, 0.9 (1.3). One hundred and eight patients (43.4%) had MetS at baseline. During follow-up, 116 (46.6%) patients accrued at least one new point in the SDI damage index. In multivariable analyses, the presence of MetS was a predictor of the development of new damage (HR: 1.54 (1.05–2.26); p < 0.029). Conclusions: The presence of MetS predicts the development of new damage in SLE patients, despite other well-known risk factors for such occurrence.

Original language	English
Pages (from-to)	105-109
Number of pages	5
Journal	Lupus
Volume	31
Issue number	1
DOIs	https://doi.org/10.1177/09612033211061481
State	Published - Jan 2022

Bibliographical note

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Almenara Lupus Cohort was partially supported by institutional grants from EsSalud (1483-GCGP-ESSALUD-2013, 1733-GCGP-ESSALUD-2014 and the 2015 Kaelin Prize 04-IETSI-ESSALUD-2016), from the Pan American League of Associations for Rheumatology (PANLAR) (2015 PANLAR Prize and the 2018 H. Ralph Schumacher MD/JCR/PANLAR Prize), and from the Fundación Instituto Hipólito Unanue and an unrestricted grant from Janssen.

Publisher Copyright:
© The Author(s) 2022.

Access to Document

10.1177/09612033211061481

Cite this

Elera-Fitzcarrald, C., Reatégui-Sokolova, C., Gamboa-Cárdenas, R. V., Medina, M., Zevallos, F., Pimentel-Quiroz, V. R., Cucho-Venegas, J. M., Alfaro-Lozano, J. L., Rodriguez-Bellido, Z., Pastor-Asurza, C. A., Perich-Campos, R., Alarcón, G. S., & Ugarte-Gil, M. F. (2022). Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. Lupus, 31(1), 105-109. https://doi.org/10.1177/09612033211061481

@article{85fbf3b95bfb4179889146ea939510fc,

title = "Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort",

abstract = "Objectives: This study aims to determine whether the MetS predicts damage accrual in SLE patients. Methods: This longitudinal study was conducted in a cohort of consecutive SLE patients seen since 2012 at one single Peruvian institution. Patients had a baseline visit and then follow-up visits every 6 months. Patients with ≥ 2 visits were included. Evaluations included interview, medical records review, physical examination, and laboratory tests. Damage accrual was ascertained with the SLICC/ACR damage index (SDI) and disease activity with the SLEDAI-2K. Univariable and multivariable Cox-regression survival models were carried out to determine the risk of developing new damage. The multivariable model was adjusted for age at diagnosis; disease duration; socioeconomic status; SLEDAI; baseline SDI; the Charlson Comorbidity Index; daily dose; and time of exposure of prednisone (PDN), antimalarials, and immunosuppressive drugs. Results: Two hundred and forty-nine patients were evaluated; 232 of them were women (93.2%). Their mean (SD) age at diagnosis was 35.8 (13.1) years; nearly all patients were Mestizo. Disease duration was 7.4 (6.6) years. The SLEDAI-2K was 5.2 (4.3) and the SDI, 0.9 (1.3). One hundred and eight patients (43.4%) had MetS at baseline. During follow-up, 116 (46.6%) patients accrued at least one new point in the SDI damage index. In multivariable analyses, the presence of MetS was a predictor of the development of new damage (HR: 1.54 (1.05–2.26); p < 0.029). Conclusions: The presence of MetS predicts the development of new damage in SLE patients, despite other well-known risk factors for such occurrence.",

author = "Claudia Elera-Fitzcarrald and Cristina Reat{\'e}gui-Sokolova and Gamboa-C{\'a}rdenas, {Roc{\'i}o V.} and Mariela Medina and Francisco Zevallos and Pimentel-Quiroz, {Victor R.} and Cucho-Venegas, {Jorge M.} and Alfaro-Lozano, {Jos{\'e} L.} and Zoila Rodriguez-Bellido and Pastor-Asurza, {Cesar A.} and Risto Perich-Campos and Alarc{\'o}n, {Graciela S.} and Ugarte-Gil, {Manuel F.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2022",

month = jan,

doi = "10.1177/09612033211061481",

language = "Ingl{\'e}s",

volume = "31",

pages = "105--109",

journal = "Lupus",

issn = "0961-2033",

publisher = "SAGE Publications Ltd",

number = "1",

}

Elera-Fitzcarrald, C, Reatégui-Sokolova, C, Gamboa-Cárdenas, RV, Medina, M, Zevallos, F, Pimentel-Quiroz, VR, Cucho-Venegas, JM, Alfaro-Lozano, JL, Rodriguez-Bellido, Z, Pastor-Asurza, CA, Perich-Campos, R, Alarcón, GS & Ugarte-Gil, MF 2022, 'Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort', Lupus, vol. 31, no. 1, pp. 105-109. https://doi.org/10.1177/09612033211061481

TY - JOUR

T1 - Metabolic syndrome predicts new damage in systemic lupus erythematosus patients

T2 - Data from the Almenara Lupus Cohort

AU - Elera-Fitzcarrald, Claudia

AU - Reatégui-Sokolova, Cristina

AU - Gamboa-Cárdenas, Rocío V.

AU - Medina, Mariela

AU - Zevallos, Francisco

AU - Pimentel-Quiroz, Victor R.

AU - Cucho-Venegas, Jorge M.

AU - Alfaro-Lozano, José L.

AU - Rodriguez-Bellido, Zoila

AU - Pastor-Asurza, Cesar A.

AU - Perich-Campos, Risto

AU - Alarcón, Graciela S.

AU - Ugarte-Gil, Manuel F.

PY - 2022/1

Y1 - 2022/1

N2 - Objectives: This study aims to determine whether the MetS predicts damage accrual in SLE patients. Methods: This longitudinal study was conducted in a cohort of consecutive SLE patients seen since 2012 at one single Peruvian institution. Patients had a baseline visit and then follow-up visits every 6 months. Patients with ≥ 2 visits were included. Evaluations included interview, medical records review, physical examination, and laboratory tests. Damage accrual was ascertained with the SLICC/ACR damage index (SDI) and disease activity with the SLEDAI-2K. Univariable and multivariable Cox-regression survival models were carried out to determine the risk of developing new damage. The multivariable model was adjusted for age at diagnosis; disease duration; socioeconomic status; SLEDAI; baseline SDI; the Charlson Comorbidity Index; daily dose; and time of exposure of prednisone (PDN), antimalarials, and immunosuppressive drugs. Results: Two hundred and forty-nine patients were evaluated; 232 of them were women (93.2%). Their mean (SD) age at diagnosis was 35.8 (13.1) years; nearly all patients were Mestizo. Disease duration was 7.4 (6.6) years. The SLEDAI-2K was 5.2 (4.3) and the SDI, 0.9 (1.3). One hundred and eight patients (43.4%) had MetS at baseline. During follow-up, 116 (46.6%) patients accrued at least one new point in the SDI damage index. In multivariable analyses, the presence of MetS was a predictor of the development of new damage (HR: 1.54 (1.05–2.26); p < 0.029). Conclusions: The presence of MetS predicts the development of new damage in SLE patients, despite other well-known risk factors for such occurrence.

AB - Objectives: This study aims to determine whether the MetS predicts damage accrual in SLE patients. Methods: This longitudinal study was conducted in a cohort of consecutive SLE patients seen since 2012 at one single Peruvian institution. Patients had a baseline visit and then follow-up visits every 6 months. Patients with ≥ 2 visits were included. Evaluations included interview, medical records review, physical examination, and laboratory tests. Damage accrual was ascertained with the SLICC/ACR damage index (SDI) and disease activity with the SLEDAI-2K. Univariable and multivariable Cox-regression survival models were carried out to determine the risk of developing new damage. The multivariable model was adjusted for age at diagnosis; disease duration; socioeconomic status; SLEDAI; baseline SDI; the Charlson Comorbidity Index; daily dose; and time of exposure of prednisone (PDN), antimalarials, and immunosuppressive drugs. Results: Two hundred and forty-nine patients were evaluated; 232 of them were women (93.2%). Their mean (SD) age at diagnosis was 35.8 (13.1) years; nearly all patients were Mestizo. Disease duration was 7.4 (6.6) years. The SLEDAI-2K was 5.2 (4.3) and the SDI, 0.9 (1.3). One hundred and eight patients (43.4%) had MetS at baseline. During follow-up, 116 (46.6%) patients accrued at least one new point in the SDI damage index. In multivariable analyses, the presence of MetS was a predictor of the development of new damage (HR: 1.54 (1.05–2.26); p < 0.029). Conclusions: The presence of MetS predicts the development of new damage in SLE patients, despite other well-known risk factors for such occurrence.

UR - http://www.scopus.com/inward/record.url?scp=85122476121&partnerID=8YFLogxK

U2 - 10.1177/09612033211061481

DO - 10.1177/09612033211061481

M3 - Artículo

AN - SCOPUS:85122476121

SN - 0961-2033

VL - 31

SP - 105

EP - 109

JO - Lupus

JF - Lupus

IS - 1

ER -

Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this